Last reviewed · How we verify

NCT04722809: Botox

Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology

Terminated Phase 3 Last updated 26 August 2024
What this trial tests

Phase 3 trial testing Botulinum toxin injection in Bruxism in 1 participant. Terminated before completion.

Timeline
25 May 2022
Primary endpoint
31 August 2022
31 August 2022

Quick facts

Lead sponsorCentre Hospitalier Universitaire Dijon
PhasePhase 3
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment1
Start date25 May 2022
Primary completion31 August 2022
Estimated completion31 August 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire Dijon

Who can join

Adults 18 to 64, any sex, with Bruxism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bruxism is defined as a parafunction that consists of a clenching of the jaw and/or grinding of the teeth. It can occur when an individual is sleeping or awake or it can be mixed. Most often, it is primary or idiopathic bruxism, however when it is related to a cause it is qualified as secondary. Primary bruxism is a condition that is not well known to the general public, but I is very widespread (12% of the adult population). In addition, it can alter quality of life, as a result of associated sleep disorders, concentration disorders, daytime fatigue, chronic pain, etc. The current treatment for this condition is only symptomatic. Currently, one of the most effective treatments is the intramuscular injection of botulinum toxin A in the muscles of mastication. The progressive anticholinergic action results in a reduction of functional signs (dental pain, periodontal pain, temporomandibular joint pain, tension headaches, neck pain) and physical signs (reduction of the mass of the injected muscles, alba linea, tongue scalloping, limitation or stability of dental damage). However, these clinical data are practically not objectified in daily practice. Objective criteria would make it possible to measure the effectiveness of the treatment, to follow the patient, and to identify the early symptoms in order to prevent a recurrence. The aim of the prospective study is to concretely measure the strength and electromyographic activity of the muscles of mastication before and after botulinum toxin injection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Botulinum toxin injection

Trials testing the same drug.

Other recruiting trials for Bruxism

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire Dijon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04722809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing